

PI3806USw

Remarks

Currently Claims 20-29, 31-34, 38-53, 55-73, 75-90, 92-105 and 107-129 are pending. Claims 30, 54, 74, 91 and 106 are cancelled. Claims 29, 44, 47, 51, 56, 65, 68, 71, 76, 82, 85, 88, 93, 101, 108, 114, 116, 118, 120, 122, 123, 125, 128 and 129 are amended herein.

Claims 29, 47, 68, 85 and 101 are amended to remove the inadvertent duplicate recitation of 2-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(3,5-bis-trifluoromethyl-phenyl)ethyl]-methyl-amide and to remove the recitation of 2-(S)-(4-Fluoro-2-methyl-phenyl)-4-(piperidine-4-carbonyl)-piperazine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide.

Claims 44, 51, 65, 71, 82, 88, 116, 118, 120, 122 and 125 are amended to correct an obvious typographical error in the spelling of citalopram.

Claims 56, 76, 93, 108, 114 and 123 are amended to recite the more generic compound name 2-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(3,5-bis-trifluoromethyl-phenyl)ethyl]-methyl-amide. This amendment broadens, rather than narrows the scope of the claim as the previously specifically-recited enantiomer is still encompassed by the current claim language "... or an enantiomer...thereof." Support for the broader claim language is found in Applicants original specification including at page 8, lines 19-20 and original claim 10. No new matter is added.

Claim 128 is amended to correct an inadvertent clerical error and claim 129 is amended to depend from claim 128.

Entry of the foregoing amendments is respectfully requested.

Information Disclosure Statement


Applicants acknowledge with appreciation the Examiner's diligence in returning the Initialed PTO-1449's. Two additional Supplemental Information Disclosure Statements, together with the requisite PTO-1449 forms were filed

PI3806USw

on 3 May 2004 and 18 May 2004, respectively. The Examiner's consideration of the references identified and return of the initialed PTO-1449s is respectfully requested.

Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. The Examiner is invited to contact the undersigned at 919 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 4 August, 2004
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
Lorie.A.Morgan@gsk.com